In the Canakinumab Anti-inflammatory Thrombosis Outcome Trial (CANTOS), lowering high-sensitivity C-reactive protein (hs-CRP) below 2 mg/L resulted in a 25% reduction in major adverse cardiovascular events (p<0.001) and a 31% reduction in cardiovascular mortality (p<0.0001), despite no change in low-density lipoprotein cholesterol (LDL-C).

Authors

• Person: Not available Organization: National Lipid Association
  EBM Tools for Practice: Best Biomarkers for Inflammation

Sources

• EBM Tools for Practice: Best Biomarkers for Inflammation www.lipid.org National Lipid Association via serper

Referenced by nodes (4)

• high-sensitivity C-reactive protein concept
• cardiovascular events concept
• low-density lipoprotein cholesterol concept
• cardiovascular mortality concept